Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
bioRxiv ; 2024 Aug 30.
Article in English | MEDLINE | ID: mdl-39257740

ABSTRACT

Although the basal ganglia (BG) plays a central role in the motor symptoms of Parkinson's disease, few studies have investigated the influence of parkinsonism on movement-related activity in the BG. Here, we studied the perimovement activity of neurons in globus pallidus internus (GPi) of non-human primates before and after the induction of parkinsonism by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuronal responses were equally common in the parkinsonian brain as seen prior to MPTP and the distribution of different response types was largely unchanged. The slowing of behavioral reaction times and movement durations following the induction of parkinsonism was accompanied by a prolongation of the time interval between neuronal response onset and movement initiation. Neuronal responses were also reduced in magnitude and prolonged in duration after the induction of parkinsonism. Importantly, those two effects were more pronounced among decrease-type responses, and they persisted after controlling for MPTP-induced changes in the trial-by-trial timing of neuronal responses. Following MPTP The timing of neuronal responses also became uncoupled from the time of movement onset and more variable from trial-to-trial. Overall, the effects of MPTP on temporal features of neural responses correlated most consistently with the severity of parkinsonian motor impairments whereas the changes in response magnitude and duration were either anticorrelated with symptom severity or inconsistent. These findings point to a potential previously underappreciated role for abnormalities in the timing of GPi task-related activity in the generation of parkinsonian motor signs.

2.
Cancer Discov ; 10(9): 1352-1373, 2020 09.
Article in English | MEDLINE | ID: mdl-32571778

ABSTRACT

A hallmark of metastasis is the adaptation of tumor cells to new environments. Metabolic constraints imposed by the serine and glycine-limited brain environment restrict metastatic tumor growth. How brain metastases overcome these growth-prohibitive conditions is poorly understood. Here, we demonstrate that 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the rate-limiting step of glucose-derived serine synthesis, is a major determinant of brain metastasis in multiple human cancer types and preclinical models. Enhanced serine synthesis proved important for nucleotide production and cell proliferation in highly aggressive brain metastatic cells. In vivo, genetic suppression and pharmacologic inhibition of PHGDH attenuated brain metastasis, but not extracranial tumor growth, and improved overall survival in mice. These results reveal that extracellular amino acid availability determines serine synthesis pathway dependence, and suggest that PHGDH inhibitors may be useful in the treatment of brain metastasis. SIGNIFICANCE: Using proteomics, metabolomics, and multiple brain metastasis models, we demonstrate that the nutrient-limited environment of the brain potentiates brain metastasis susceptibility to serine synthesis inhibition. These findings underscore the importance of studying cancer metabolism in physiologically relevant contexts, and provide a rationale for using PHGDH inhibitors to treat brain metastasis.This article is highlighted in the In This Issue feature, p. 1241.


Subject(s)
Antineoplastic Agents/therapeutic use , Brain Neoplasms/drug therapy , Brain/pathology , Phosphoglycerate Dehydrogenase/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Brain/metabolism , Brain Neoplasms/secondary , Cell Line, Tumor , Datasets as Topic , Drug Resistance, Neoplasm , Female , Gene Knockdown Techniques , Glycine/analysis , Glycine/metabolism , Humans , Metabolomics , Mice , Phosphoglycerate Dehydrogenase/genetics , Phosphoglycerate Dehydrogenase/metabolism , Proteomics , RNA-Seq , Serine/analysis , Serine/metabolism , Tumor Microenvironment/drug effects , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL